SAN
DIEGO, Jan. 5, 2024 /PRNewswire/ -- Illumina Inc.
(NASDAQ: ILMN), a global leader in DNA sequencing and array-based
technologies, today announced it has signed an agreement with
Janssen Research & Development, LLC (Janssen). This
collaboration will be the first relating to the development of
Illumina's novel molecular residual disease (MRD) assay, a
whole-genome sequencing (WGS) multi-cancer research solution that
detects circulating tumor DNA (ctDNA) to better understand the
persistence or recurrence of disease following clinical
intervention.
In oncology, MRD testing is increasingly being used as
a prognostic indicator of disease recurrence after treatment by
helping clinicians assess the effectiveness of a patient's current
course of clinical intervention and guide their decisions about
precision therapy. MRD testing for solid tumors shows promise for
improving the standard of care where current disease-monitoring
tools fall short in accurately identifying patients' response
to treatment.
"This collaboration reflects the value of our unique MRD
technology and the promise of Illumina's whole-genome approach in
oncology," said Joydeep Goswami,
chief strategy and corporate development officer and chief
financial officer of Illumina. "Working together with pharma
partners like Janssen, we aim to deliver a sensitive, accurate, and
easily accessible whole-genome sequencing MRD assay to advance
clinical research in oncology."
The Illumina WGS MRD assay, which is currently in development,
will detect ctDNA for MRD assessment in research settings that
evaluate samples from patients previously diagnosed with cancer
across multiple solid tumor indications. In contrast with
existing MRD solutions with complex workflows, Illumina plans to
develop a research solution that will provide a cost-effective,
highly sensitive, and automated workflow, with the potential to
achieve a turnaround time of five to seven days.
Illumina intends to collaborate with other leaders in pharma to
help further develop and expand the utility of its WGS MRD
assay.
Use of forward-looking statements
This article may
contain forward-looking statements that involve risks and
uncertainties. Among the important factors to which our business is
subject that could cause actual results to differ materially from
those in any forward-looking statements are challenges inherent in
developing, manufacturing, and launching new products and services,
and our ability to successfully partner with other companies and
organizations to develop new products, expand markets, and grow our
business, together with other factors detailed in our filings with
the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to
update these forward-looking statements, to review or confirm
analysts' expectations, or to provide interim reports or updates on
the progress of the current quarter.
About Illumina
Illumina is improving human health by
unlocking the power of the genome. Our focus on innovation has
established us as a global leader in DNA sequencing and array-based
technologies, serving customers in the research, clinical, and
applied markets. Our products are used for applications in the life
sciences, oncology, reproductive health, agriculture, and other
emerging segments. To learn more, visit illumina.com and connect
with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and
YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
David McAlpine
347-327-1336
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-expands-collaboration-with-janssen-to-advance-molecular-residual-disease-cancer-test-302026993.html
SOURCE Illumina, Inc.